Background-Cell therapy is a promising option to improve functional recovery after ischemia. Several subsets of bone marrow-derived cells were shown to reduce infarct size and increase ejection fraction in experimental models of ischemia. The mechanisms underlying the functional improvement are diverse and have been shown to include paracrine effects of the injected cells, as well as a variable degree of differentiation to endothelial cells, pericytes, smooth muscle, and cardiac muscle. Methods and Results-To elucidate the true nature of such plasticity and contribution to recovery, we engineered vectors that encoded inducible suicide genes under the control of endothelium (endothelial nitric oxide synthase)-, smooth muscle (SM22␣)-, and cardiomyocyte (␣-MHC)-specific promoters, thereby allowing selective depletion of the individual cell lineage acquired by the transplanted undifferentiated bone marrow-derived cells. Lentivirally delivered thymidine kinase, which converts the prodrug ganciclovir into a cytotoxic agent, was used to selectively eliminate cells 2 weeks after transplantation of bone marrow mononuclear cells in an acute myocardial infarction model. We demonstrate that elimination of transplanted endothelium-committed or SM22␣-expressing cells, but not cardiaccommitted cells, induced a significant deterioration of ejection fraction. Moreover, elimination of endothelial nitric oxide synthase-expressing cells 2 weeks after injection reduced capillary and arteriole density.
C ell therapy is a promising option to restore cardiac function after ischemia or during heart failure. Various subsets of adult bone marrow-derived or tissue-resident progenitor cells were shown to augment the recovery of cardiac function after ischemia in experimental models. Most clinical studies to date have been performed with total bone marrow mononuclear cells (BMCs), which comprise hematopoietic progenitor cells, mesenchymal stem cells, and monocytes. Treatment of patients with acute myocardial infarction with BMCs induced a modest increase in ejection fraction and beneficially interfered with left ventricular remodeling processes in most but not all studies. 1 However, the mechanisms underlying the functional improvement are discussed controversially, and the long-term engraftment and differentiation were variable between the studies. Because cardiac function was improved in some studies even in the absence of significant long-term engraftment and differentiation of the injected cells, it has been speculated that paracrine mechanisms might be responsible for the therapeutic benefit achieved by bone marrow-derived cells (for review, see Gnecchi et al 2 ) . Meanwhile, various studies confirmed that progenitor cells release paracrine factors that modulate angiogenesis, cardiomyocyte apoptosis, fibrosis, and inflammation, and various cytokines and growth factors have been identified in progenitor cells that mechanistically contribute to these powerful paracrine effects (for review, see Burchfield and Dimmeler 3 ) . Although there is no doubt that paracrine effects contribute to the enhanced functional recovery after cardiac ischemia, the extent and duration of engraftment and differentiation of the applied cells are still under debate. On the basis of the discovery that a subset of CD34ϩ hematopoietic progenitor cells can differentiate to endothelial cells, 4 various groups investigated the vasculogenic activity of bone marrow-derived cells. Injected total BMCs, CD34ϩ cells, mesenchymal stem cells, and various other bone marrow-derived cells were detected in newly formed blood vessels, some of which contributed to the inner layer of endothelial cells, whereas others (eg, Tie2-positive bone marrow-derived cells) were more profoundly detected in the perivascular space, which suggests a pericyte function. [5] [6] [7] [8] [9] Bone marrow-derived progenitor cells also formed robust and long-lasting functional vascular networks in vivo when tissue engineering approaches were used. 10 However, transplant models raised some doubts about whether endogenously mobilized bone marrow-derived cells can indeed form endothelial cells in tumor or arteriogenesis models. 11 Even more intensely debated is the question of whether bone marrowderived cells can acquire a cardiac fate. Although selected murine c-kit-positive or human CD34ϩ bone marrow-derived cells showed robust engraftment and differentiation of the injected cells in all cardiovascular lineages in some studies, 12, 13 others failed to detect cardiac-committed bone marrow-derived cells. 14 
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The different rates of cell retention, survival, and differentiation in the studies may reflect multiple ways to deliver cells, 15, 16 the use of different progenitor cell subsets, 17 and the specific techniques used to detect the cells. In particular, immunofluorescence staining has been accused of yielding false-positive results. However, using bioluminescence imaging with firefly luciferase to detect living engrafted cells, van der Bogt et al 17 demonstrated that injected BMCs were still detected up to 6 weeks after injection. The engraftment of BMCs up to 6 weeks after injection was further confirmed by polymerase chain reaction. 17 In line with these findings, selective killing of injected cultured endothelial progenitor cells by thymidine kinase (TK) activation 2 weeks after injection was shown to be associated with deterioration of cardiac function, 18 which indicates that at least in some of the studies, longer-term engraftment could be detected by different methods. Although these studies do not address the extent and role of cell differentiation, they do support the observation that bone marrow-derived cells are detectable and might exhibit longer-term functions.
To address the extent and functional relevance of cardiovascular cell fate acquisition, we engineered vectors encoding inducible suicide genes under the control of lineage-specific promoters, thereby allowing selective depletion of the individual cell lineage acquired by the transplanted undifferentiated human BMCs. Specifically, we used the endothelial nitric oxide synthase (eNOS) promoter (eNOSp), the transgelin (SM22-␣) promoter (SM22p), and the ␣-myosin heavy chain (␣-MHC) promoter (MHCp) to target endothelial cells, smooth muscle cells/fibroblasts, and cardiomyocytes, respectively.
Methods

Cell Culture
BMCs from healthy volunteers were isolated from bone marrow aspirates by density gradient centrifugation as described previously. 19 The majority (Ͼ90%) of the isolated BMCs were CD45ϩ, and Ϸ70% expressed the monocyte and endothelial marker CD31. Approximately 50% expressed the lymphocyte marker CD3, and 10% were CD14ϩ. Only a small fraction of cells (Ͻ5%) were CD34ϩ, and mesenchymal cells (which express CD73 and give rise to colony-forming-unit fibroblasts) were Ͻ2%. Pooled human umbilical vein endothelial cells (HUVECs) and human aortic smooth muscle cells were purchased from Lonza (Verviers, Belgium). Cardiomyocytes were isolated from hearts of neonatal rats by collagenase digestion.
Lentiviral Vectors and Transduction
Lentiviral vectors that contained the enhanced green fluorescent protein (eGFP) gene or the viral TK gene of the herpes simplex type II virus and a woodchuck posttranscriptional regulatory element were generated as described previously. 18 For lineage tracing, the constitutively active promoter (spleen focus-forming virus promoter) was replaced by the human eNOS promoter (accession number AF387340), the human SM22-␣ promoter (GenBank accession number FJ858739), and murine ␣-MHC promoter (GenBank accession number U71441) to control expression of either green fluorescent protein (GFP) or TK. HUVECs, smooth muscle cells, and cardiomyocytes were transduced by the addition of viral supernatant to the specific medium. After 24 hours, medium was changed and a second transduction was performed. To facilitate BMC transduction, dishes were coated with RetroNectin (Takara, Shiga, Japan), and viral supernatant was added for 2 hours at 37°C. After the supernatant was aspirated, the culture dishes were washed with PBS and then plated with freshly isolated BMCs in endothelial growth medium with 20% fetal calf serum. After 2 days, lentiviral transduction was repeated by adding viral supernatant to the plated cells.
Acute myocardial infarction was induced in male nu/nu mice (8 to 10 weeks; Harlan, Indianapolis, Ind) by permanent ligation of the apical branch of the left anterior coronary artery. A total of 1 million BMCs were resolved in 50 L of PBS intramuscularly at 4 points in the border zone distal to the ligation of the coronary artery immediately after induction of the infarction. Echocardiography was performed with high-resolution echocardiography (Vevo 770 smallanimal micro-ultrasound system, VisualSonics, Toronto, Canada).
Statistical Analysis
SPSS 11.0.1 (SPSS, Chicago, Ill) was used for statistical analysis of the data. Mortality rates after ganciclovir administration between TK-BMC and GFP-BMC were compared by Kaplan-Meier curves and log-rank analysis. Repeated-measures ANOVA was used for comparison of end-diastolic volume, end-systolic volume, and ejection fraction between GFP-BMC and PBS groups. Continuous data were analyzed by Mann-Whitney test between 2 groups or by 1-way ANOVA test and then Bonferroni post hoc analysis for more than 2 groups. For further details, including protocols for immunostaining, see the online-only Data Supplement.
Results
Establishment of Transduction Protocols
Given that the composition and specific isolation protocols of the injected cells may influence cell engraftment, BMCs were isolated according to the protocol used in the placebo-controlled, randomized, double-blind, multicenter REPAIR-AMI (Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial, which demonstrated significantly increased left ventricular contractile recovery and improved clinical outcome in the BMC group. 19 Lentivirally delivered GFP was used to determine transduction efficiency. Approximately one third of the BMCs expressed GFP after viral transduction (Figure 1a and 1b). To determine which cell types of the heterogenous BMC population were preferentially targeted by lentiviral transduction, we selected hematopoietic CD34ϩ progenitor cells, CD14ϩ myeloid cells, and CD3ϩ lymphocytes by means of magnetic beads. Although Ϸ40% to 50% of CD34ϩ and CD14ϩ cells and Ͼ90% of cultured mesenchymal cells expressed GFP, CD3ϩ lympho-cytes were not transduced by the vector (Figure 1b ). Next, we delivered the suicide gene TK, which activates the prodrug ganciclovir to induce cell death. 18, 20 Ganciclovir induced toxicity in Ϸ50% of the TK-transduced BMCs and eliminated all outgrowing mesenchymal colonies (Figure 1c and 1d ).
Engraftment and Functional Activity of GFP-Transduced BMCs
To determine clonal expansion and functional incorporation of lentivirus-transduced BMCs into vasculogenic lineages in vitro, we used a recently described coculture system in which endothelial cells were shown to form vessel-like structures on fibroblast or mesenchymal cells. 21 After GFP-transduced BMCs were cocultured with endothelial cells on fibroblast monolayers, GFP-positive vessel-like structures were observed ( Figure 2a ). We confirmed that these cells expressed an endothelial marker (von Willebrand factor) and were connected with HUVECs ( Figure 2b ). Likewise, implantation of GFP-transduced BMCs in Matrigel plugs in vivo revealed that GFP-expressing cells contributed to newly formed perfused vessels ( Figure 2c ) and expressed either the endothelial marker von Willebrand factor or the pericyte/smooth muscle markers ␣-smooth muscle actin or platelet-derived growth factor receptor-␤ ( Figure 2d ), which demonstrates the vasculogenic activity of BMCs in vivo.
Next, we determined the functional effects and incorporation of GFP-transduced human BMCs in mice after myocardial ischemia. Because of a high intraindividual and interindividual variability of echocardiographically measured systolic function at 1 position in murine myocardial infarction models, we performed sequential high-resolution echocardiography at 3 defined positions (apex, mid, and base) and then calculated volumetric indexes and ejection fraction (Figure 3a; for details, see the online-only Data Supplement). Intramyocardially injected GFP-BMCs significantly improved global left ventricular ejection fraction (Pϭ0.039) and reduced end-systolic volume expansion (Pϭ0.05) 4 weeks after induction of myocardial infarction compared with PBS-treated control mice ( Figure  3b ). At 2 weeks, incorporated GFP-positive human cells were detected by use of en face fluorescence microscopy of the freshly isolated heart (Figure 4a ), particularly in the infarct and border zone. GFP-positive cells were predominantly detected in or around capillaries or in the interstitial space and resembled fibroblasts (Figure 4b through 4d ). Approximately 75% of GFP-positive cells resembled fibroblasts, 24% showed endothelial characteristics, and only a few (Ͻ1%) coexpressed the cardiac marker troponin T.
Depletion of Total BMCs Reduces Cardiac Function and Vascularization
To determine the effect of cell ablation on heart function, we injected TK-transduced BMCs (TK-BMCs) or GFP-BMCs in mice immediately after myocardial infarction and induced cell depletion by ganciclovir at 2 weeks after acute myocardial infarction. Administration of ganciclovir selectively increased mortality in mice that had received TK-BMCs, whereas no effect was observed in mice that received GFP-BMCs lacking the suicide gene (PϽ0.05 between groups; Figure 4e ). Consistent with the induction of mortality in the TK-BMC group, ganciclovir treatment significantly reduced left ventricular ejection fraction within 3 days after ganciclovir treatment in the TK-BMC group, whereas no effect was seen when GFP-BMCs were implanted before treatment with ganciclovir ( Figure 4f ). Moreover, ganciclovir treatment abrogated the increase in capillary density and smooth muscle cells in the TK-BMC group but not in the GFP-BMC group ( 4g and 4h). As a second control group, we injected TK-transduced HUVECs, which did not improve cardiac function (a finding that is consistent with previous studies 22, 23 ). Depletion of TK-HUVECs did not induce a deterioration of cardiac function (Figure 4f ).
Generation of Lentiviral Vectors Allowing Lineage-Restricted Expression of GFP or TK
To selectively eliminate cells that acquired a cardiovascular cell fate after injection, as indicated by reexpression of endothelial, smooth muscle, or cardiac marker genes, we constructed vectors Figure 5a ). GFP expression was documented in endothelial cells (HUVECs), smooth muscle cells, and cardiomyocytes when eNOSp-GFP, SM22p-GFP, and MHCp-GFP constructs were transduced, respectively (Figure 5b and 5c ). The specificity of the constructs was confirmed by the absence of expression of eNOSp-GFP in smooth muscle cells and of MHCp-GFP in endothelial cells (Figure 5b) . Moreover, consistent with the undifferentiated state, only a very few GFP-positive cells were detected in human BMCs transduced with the eNOSp-GFP or MHCp-GFP constructs (data not shown). SM22p-GFP, however, was detected in adherent mesenchymal cells (Figure 5b ). When virally delivered TK under the control of the identical promoters was used, ganciclovir induced toxicity in SM22p-TKexpressing BMCs but not in eNOSp-TK-or MHCp-TK-expressing undifferentiated BMCs (Figure 5d ). After transplantation of eNOSp-GFP-, SM22p-GFP-, and MHCp-GFP-transduced BMCs in nude mice after acute myocardial infarction, GFPpositive cells were preferentially detectable in the border and infarct zones, which indicates that environmental cues induced the onset of expression of lineage-committed genes in the transplanted BMCs in vivo (Figure 6a through 6e) . Consistent with the endothelial expression pattern of eNOS detected in the developing and adult heart, 24 eNOSp-GFP was preferentially observed in capillaries, which were not stained with mousespecific BS-1 lectin (Figure 6a and 6b ). Human-specific von Willebrand factor staining confirmed the incorporation of these endothelial cell-committed GFP-positive cells (Figure 6a and 6b). SM22p-GFP was detected in smooth muscle cells but predominantly in cells that resembled fibroblasts, as confirmed by demonstration of expression of fibroblast-specific protein 1 (Figure 6c through 6e ). In the MHCp-GFP group, troponin T-coexpressing cardiomyocytes were detected occasionally ( Figure 6f ). Overall, SM22-GFP-expressing cells were detectable with the highest frequency in the border zone of infarcted hearts (Figure 6g ). Although at a lower incidence, eNOS-GFP cells contributed to approximately 40 cells/mm 2 (which reflects 1.3% of the total number of cells), whereas the absolute number of detectable ␣-MHC-GFP-positive cells was very low (Ͻ0.1% of the total number of cells; Figure 6g ).
Effect of Selective Elimination of Lineage-Committed BMCs In Vivo
To determine the contribution of the subset of BMCs that reexpressed lineage-specific genes to the maintenance of cardiac function after cell therapy, lineage-specific TKexpressing BMCs were injected in nude mice immediately after myocardial infarction, and TK-expressing cells were eliminated by administration of ganciclovir after 2 weeks. Interestingly, after administration of ganciclovir, the survival of mice transplanted with lineage-committed TK-BMCs was superior to that of the TK-BMC group in which all lineages were traced by the vector (Figure 7a ), which indicates that global depletion of all cells had more functional consequences than elimination of 1 of the 3 lineage-committed cell subsets. However, when we measured cardiac function by echocardiography, the eNOSp-TK group showed a profound and highly significant deterioration of left ventricular ejection fraction and a trend toward end-systolic volume expansion from 2 to 4 weeks when ganciclovir was injected at 2 weeks to deplete the cells (Figure 7b through 7d ). Depletion of SM22p-TK BMCs also significantly reduced left ventricular ejection fraction, whereas selective killing of MHCexpressing cells did not significantly impair cardiac function, although a trend toward worsening of left ventricular ejection fraction was detectable (Figure 7b and 7c ). Analysis of individual regions within the ventricle illustrates that the global reduction of ejection fraction in the eNOSp-TK group was predominantly caused by a deterioration of contractility in the apex and mid region, where myocardial infarction had been induced initially (Figure 7b ). Paralleling the profound reduction in contractile function was a significant reduction of capillary and smooth muscle actin-positive vessel density after depletion of eNOS-expressing BMCs, whereas depletion of cardiac-committed MHC-expressing cells did not influence vascularization (Figure 7e and 7f) . Surprisingly, elimination of SM22-expressing cells also affected capillary den- sity, but smooth muscle actin-positive vessels were not significantly reduced either when the total number of smooth muscle actin-positive cells was analyzed or when the small and large arteries were counted selectively (Figure 7f and data not shown). The functional importance of capillary density was further substantiated by the close correlation of left ventricular ejection fraction with capillary density at 4 weeks (Figure 7g ).
Analysis of Bystander Effects
It is well established that the activated prodrug ganciclovir can elicit an unspecific bystander effect on neighboring cells that may enhance the cytotoxicity of ganciclovir. Although we demonstrated in previous studies that the supernatant of ganciclovir-treated endothelial progenitor cells does not induce a cytotoxic effect on cultured cardiomyocytes or endothelial cells, 18 we did not address the effect of ganciclovir- induced cell death on physically associated cocultured cells. Therefore, we cocultured TK-expressing cells with nontransduced cells and induced cell death in the TK-expressing cells by adding ganciclovir. When 10% of TK-expressing HUVECs were cultured with 90% of GFP-transduced HUVECs (1:9 ratio), cell viability dropped to 30%, which indicates that roughly 60% of the HUVECs were killed by bystander effects (online-only Data Supplement Figure Ia and Ib). However, when TK-transduced progenitor cells were cocultured with HUVECs at a ratio of 1:9, viability of HUVECs was not affected after addition of ganciclovir (online-only Data Supplement Figure Ic and Id). Likewise, we performed an additional coculture experiment using a modified in vitro vascular tube formation assay as described above 21 by adding TK-transduced CD14ϩ cell-derived macrophages to yellow fluorescent protein-transduced HUVECs (1:9 ratio) on fibroblast monolayers. Yellow fluorescent proteintransduced HUVECs produced well-organized vessel-like structures, as shown in Figure Ie and If of the online-only Data Supplement. When we depleted macrophages by addition of ganciclovir, we did not observe a significant decrease of the tube-like structures formed by HUVECs, which indicates that selective elimination of macrophages does not severely affect the endothelial network via bystander effects. Finally, the number of terminal dUTP nick end-labeling-positive cells in TK-BMC-injected mouse hearts in vivo was only 23.5Ϯ4.0 cells/mm 2 3 days after ganciclovir treatment compared with a total of 191.4Ϯ20.3 GFP-positive incorporated BMCs per mm 2 detected in the control group, which indicates that cell death did not exceed the overall number of implanted cells.
Discussion
The present data demonstrate that among the lineages studied, BMCs reexpressing eNOS and SM22-␣ predominantly contributed to improved cardiac function 4 weeks after cell transplantation in an acute myocardial infarction model. Specifically, depletion of eNOS-expressing cells was associated with a reduction of capillary and arteriole density and induced a deterioration of regional and global left ventricular ejection fraction. The depletion of cells that expressed SM22-␣, a marker expressed in smooth muscle cells but also in fibroblasts, 25 induced a deterioration in contractile function, whereas the elimination of cells that expressed the cardiac myocyte marker ␣-MHC did not significantly affect cardiac function. Genetic studies using transgenic eNOSp reporter mice have demonstrated that eNOS expression is preferentially detected in the endothelial lining of capillaries and arteries. 24 Consistently, BMCs transduced with eNOSp-driven GFP constructs have been shown to be incorporated in capillaries. The demonstration that depletion of eNOS-expressing cells induced the most severe cardiac dysfunction suggests that the mechanism underlying the therapeutic improvement of cardiac function in acute myocardial infarction after BMC administration preferentially involves effects on vascular function and neovascularization. Various studies demonstrated that therapeutic application of total BMCs (or selected isolated hematopoietic or mesenchymal progenitor cell subsets thereof) improves blood flow recovery and capillary density after ischemia. 5, 7, 26 In particular, injected CD34ϩ and endothelial progenitor cells increased neovascularization and cardiac function in experimental models. 13 In clinical studies, BMCs specifically increased coronary blood flow reserve and reduced vascular resistance in the target vessel in patients with either acute or chronic myocardial ischemia 27, 28 and ameliorated the symptoms of intractable angina, 29 which suggests that bone marrow-derived cells target the vasculature. First evidence that capillary density may influence infarct size was provided in 1986 by Olivetti et al, 30 who showed that infarct size 30 days after ligation of the coronary artery is directly correlated with the number of capillaries in the infarct border zone. The results of the present study support these early observations by demonstrating a strong correlation between capillary density and left ventricular ejection fraction (Figure 7g) . Thus, the finding that BMCs enhance capillary density and that this contributes at least in part to the functional benefit observed is consistent with previous findings; however, the demonstration that specific depletion of eNOS-expressing cells abrogates the enhanced capillary density induced by BMCs comes as a surprise, because this would imply that the majority of the effects of BMCs are mediated by the formation of capillaries via differentiation into eNOS-expressing endothelial cells in vivo. Although we could clearly demonstrate a vasculogenic activity of BMCs in vitro, in Matrigel plug assays in vivo, and in the infarct border zone, bone marrow-derived cells (particularly endothelial progenitor cells) also promote angiogenesis by releasing paracrine factors. [31] [32] [33] [34] One explanation for the profound deterioration in left ventricular function might be that the activated cytotoxic form of ganciclovir might have induced cell death in physically connected neighboring cells, thereby enhancing the effects. Indeed, such bystander effects are well established and are even used to enhance the efficiency of tumor cell depletion. 35 To address the relevance of bystander effects, we performed 2 control experiments in vivo. In the first experiment, we investigated the effect of depleting BMCs after injection in noninjured hearts; however, induction of suicide in TK-BMCs after injection in noninjured hearts did not affect cardiac function (online-only Data Supplement Figure  II) . Second, we evaluated the effect of depleting transplanted mature vascular cells; however, depletion of TK-transduced HUVECs did not alter cardiac function (Figure 4f ), which indicates that the putative toxic effects induced by simply killing any transplanted cell are likely not the cause of the deterioration of function after depletion of BMCs.
In addition, we performed in vitro studies to more precisely determine the influence of suicide induction on neighboring cells. In these coculture assays, profound bystander effects were only detected when we cocultured suicide gene-loaded HUVECs with unmodified HUVECs, whereas coculture in the same 1:9 ratio of TK-loaded progenitor cells or macrophages with HUVECs did not profoundly affect cell death or network formation in our experience. This might be explained by the fact that HUVECs are well connected with each other in cell culture by gap junctions, which allows for the very efficient transfer of the cytotoxic drug. Progenitor cells or macrophages, however, appear less well connected with HUVECs in this in vitro assay. Furthermore, the number of terminal dUTP nick end-labeling-positive apoptotic cells in ganciclovir-treated TK-BMC-injected mouse hearts 3 days after induction of cell death by ganciclovir infusion did not exceed the number of GFP-positive cells detected in the control mice. Although this time point only represents a snapshot and does not allow us to calculate the exact sum of cells killed over the 3 days of ganciclovir injection, these data exclude a massive induction of unspecific cell death in the border zone. Moreover, the deterioration of cardiac function was more severe in the eNOS-TK group than in the SM22-TK group after ganciclovir treatment, although the number of SM22-expressing cells was 3 times as high as the number of eNOS-expressing cells. If induction of cell death, either by providing a "kiss of death" to neighboring cells or by inducing an inflammatory response, had caused a deterioration in function independent of cell fate and function, one would have expected to see a more profound response after depletion of SM22-expressing cells compared with eNOSexpressing cells; however, the present results showed a rather selective effect on regional functional recovery after depletion of eNOS-expressing cells in the apex and border zone of the infarcts that was more profound than the depletion of SM22-expressing cells.
Taken together, these data do not exclude bystander effects; however, they suggest that putative bystander effects are unlikely to account for the difference detected between the groups. Actually, it was surprising that the number of smooth muscle-positive vessels was reduced significantly after eNOS-expressing cells were eliminated and was only partially reduced after depletion of SM22-expressing cells. This might be related to the fact that in the present experiments, cells that expressed GFP under the control of the SM22 promoter did not contribute to the formation of entire new arterioles and were rarely detected in the smooth muscle layer of arteries but were incorporated preferentially around smaller capillaries in a perivascular location, or they phenotypically resembled fibroblasts. Fibroblasts are emerging as key components of normal cardiac function but also can contribute to pathological processes. 36 Interestingly, recent data demonstrate that embryonic fibroblasts can induce cycling of cardiac myocytes. 37 Therefore, the phenotypic and functional characterization of the bone marrow-derived newly generated fibroblasts deserves further detailed investigation.
Finally, the present data demonstrate that the depletion of BMCs that reexpress ␣-MHC does not induce a significant change in the global and regional function of the heart. This is consistent with the rather small number of cardiaccommitted cells seen after injection of GFP-transduced total BMCs or by detection of GFP in BMCs that had been transduced with a vector to express GFP under the control of the ␣-MHC promoter. The number of cardiac-committed cells that may have derived from differentiation or fusion events in the present study (Ͻ1%) is in the middle of the large spectrum of published data showing no cardiac commitment at all versus a high level of cardiac commitment after injection of bone marrow-derived progenitor cells. The extent of cardiac commitment in the present study was not sufficient to induce a significant response by depleting these cells.
In summary, the present data provide further mechanistic insights into the role of lineage commitment of injected human BMCs for functional regeneration after acute myocardial infarction. These data do not preclude the contribution of paracrine factors, which surely contribute to the early and probably also late beneficial effects of injected cells. However, the specific deterioration of cardiac function and reduced vascular density caused by elimination of eNOSexpressing cells suggests that this population of cells particularly contributes to the effects observed at later time points. The present study intentionally used a clinically applied preparation of BMCs that has been shown to provide a beneficial effect in patients treated with this cell preparation. 19 Although the present study is thus designed to provide insights into the mechanisms of a clinically used cell population, it has several limitations. First, we cannot entirely exclude indirect off-target effects caused by the induction of cell death, although we believe that our data showing a distinct response in cardiac function and vascularization after depletion of either eNOS-or SM22-expressing cells suggest that putative bystander effects are unlikely to fully account for the results of the present study. Second, the use of human cells requires the use of either immunodeficient or immunocompromised animals, which may have impacts on cell integration, survival, and differentiation activity. Despite these limitations, the present study is the first attempting to elucidate the functional contribution of the cardiovascular cell fate decisions of clinically applied human cells in vivo.
